It is also interesting to note that many trials using PI3K or Akt inhibitors as a single intervention, or without the use of cytotoxic chemotherapy, in the context of gynecological cancers (NCT01226316; [34], NCT01307631; [35], NCT00920257; [36], NCT01283035; [37]) showed at best moderate to absent effectiveness, even in the context of cancers presenting mutations in the PI3K/Akt/PTEN/Ras axis. The gene discussed is AKT1; the disease is cancer.